EFLA 956 (Zingiber officinale extract)

EFLA 956 is a standardized Zingiber officinale (ginger) extract containing concentrated gingerols and shogaols that inhibits inflammatory pathways. It primarily works by suppressing COX-2 enzyme activity and reducing NF-κB activation to support joint mobility and digestive health.

Origin & History

EFLA 956 is a branded standardized extract derived from Zingiber officinale (ginger) rhizome, developed by Engelhard Arzneimittel GmbH & Co. KG. It is produced through a proprietary aqueous-ethanolic extraction method followed by purification and drying, yielding a light brown powder standardized to contain ≥15% total gingerols and shogaols.

Historical & Cultural Context

Ginger rhizome has been used for over 2,500 years in Traditional Chinese Medicine and over 2,000 years in Ayurveda for treating nausea, digestive issues, inflammation, and arthritis. Known as 'adrak' (fresh) or 'shun thi' (dried) in Ayurveda, it was traditionally prepared as decoction or powder (1-3g/day) for 'vata' imbalances and cold-induced pain.

Health Benefits

• Joint mobility support - manufacturer pilot studies suggest 252mg/day may improve joint function (evidence quality: preliminary, unpublished data)
• Anti-inflammatory effects - inhibits COX-2/PGE2 pathways and reduces NF-κB activation (evidence quality: mechanistic studies)
• Antioxidant properties - upregulates Nrf2 for enhanced antioxidant gene expression including HO-1 and NQO1 (evidence quality: in-vitro data)
• Potential nausea reduction - general ginger meta-analysis shows RR 0.67 [95% CI 0.50-0.90] (PMID 25502535; evidence quality: moderate, though not EFLA 956-specific)
• Possible osteoarthritis pain relief - general ginger studies show VAS score improvements (PMID 23405820; evidence quality: moderate, not EFLA 956-specific)

How It Works

EFLA 956 contains concentrated gingerols and shogaols that inhibit cyclooxygenase-2 (COX-2) enzyme activity, reducing prostaglandin E2 (PGE2) production. The extract also suppresses nuclear factor-kappa B (NF-κB) activation, a key inflammatory transcription factor. These dual pathways result in reduced inflammatory mediator production and oxidative stress.

Scientific Research

No human clinical trials specifically on EFLA 956 are identified in PubMed-indexed literature. General ginger extract studies include an RCT (PMID 23405820) with 120 participants showing reduced knee pain in osteoarthritis using 2g/day ginger powder, and a meta-analysis (PMID 25502535) of 8 RCTs (n=664) demonstrating ginger's effectiveness for nausea. Manufacturer claims for EFLA 956 cite unpublished pilot studies using 252mg/day for joint mobility.

Clinical Summary

Preliminary manufacturer pilot studies suggest 252mg daily of EFLA 956 may improve joint function, though this data remains unpublished and requires independent verification. The evidence base consists primarily of mechanistic studies demonstrating anti-inflammatory and antioxidant properties in laboratory settings. No large-scale randomized controlled trials have been published examining EFLA 956's clinical efficacy. Current evidence quality is considered preliminary and requires further research to establish therapeutic benefits.

Nutritional Profile

EFLA 956 is a proprietary supercritical CO2 extract of Zingiber officinale (ginger) rhizome, standardized and concentrated for bioactive constituents rather than macronutrient content. Key bioactive compounds include: **Gingerols** — primarily [6]-gingerol (typically 1–3% of extract weight), along with [8]-gingerol and [10]-gingerol, which are the principal pungent phenolic compounds responsible for COX-2 and PGE2 inhibition; **Shogaols** — primarily [6]-shogaol (formed by dehydration of gingerols during processing, typically 0.5–2%), which exhibits higher bioactivity than gingerols in some anti-inflammatory and antioxidant assays; **Zingerone** — a less pungent degradation product contributing to anti-inflammatory activity; **Sesquiterpenes** — including zingiberene (20–30% of volatile oil fraction), β-sesquiphellandrene, ar-curcumene, and β-bisabolene, contributing to aromatic profile and mild bioactivity; **Paradols** — minor constituents with antioxidant properties. The supercritical CO2 extraction method used for EFLA 956 preferentially concentrates lipophilic gingerols, shogaols, and sesquiterpene hydrocarbons while excluding water-soluble polysaccharides, fiber, and most minerals. Typical dose studied is 252 mg/day (often as 2 × 126 mg capsules). Macronutrient contribution per dose is nutritionally negligible (minimal calories, protein, carbohydrate, or fiber). Micronutrient content (vitamins, minerals) is trace/insignificant at the recommended dose. **Bioavailability notes:** [6]-gingerol undergoes extensive first-pass metabolism with glucuronidation and sulfation as primary conjugation pathways, resulting in low systemic bioavailability of free gingerols (estimated <10%); however, the CO2 extraction process yields a lipophilic matrix that may enhance gastrointestinal absorption compared to aqueous ginger preparations. Gingerols and shogaols are rapidly absorbed (Tmax ~1–2 hours) but have short plasma half-lives. The concentrated extract format of EFLA 956 is designed to deliver pharmacologically relevant levels of these bioactives at lower total mass compared to crude dried ginger powder, which would require substantially higher doses (e.g., 1–2 g) to achieve comparable gingerol intake.

Preparation & Dosage

EFLA 956: 120-252mg/day of standardized extract (≥15% gingerols/shogaols) in capsule form based on manufacturer-supported trials. Generic ginger powder: 1-2g/day; standardized extracts (5% gingerols): 250-500mg/day. Maximum safe dose: 2g/day ginger equivalent per EFSA guidelines. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Piperine (black pepper extract), Boswellia serrata, Turmeric (curcumin), MSM, Glucosamine

Safety & Interactions

EFLA 956 may cause mild gastrointestinal upset, heartburn, or nausea in sensitive individuals, similar to other ginger preparations. It may interact with anticoagulant medications like warfarin due to potential blood-thinning effects. Individuals with gallstones should use caution as ginger extracts may stimulate bile production. Pregnant women should consult healthcare providers before use, as high-dose ginger extracts may affect pregnancy outcomes.